Bone Biologics effects 1-for-30 reverse stock split effective June 5, 2023

Bone Biologics Corp

1-for-30 reverse split of common stock and warrants effective June 5, 2023; par value unchanged.
Stockholder approval via written consent on May 1, 2023; no fractional shares, rounding up.
Trading on Nasdaq on split-adjusted basis from June 7, 2023; new CUSIP 098070402 (common) and 098070154 (warrants).
Proportionate adjustments to exercise prices and shares reserved under equity plans and outstanding options/warrants.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bone Biologics Corp: Amendment to Certificate of Incorporation to effect a 1-for-30 reverse stock split (effective 2023-06-05).

Change: charter amendment
Effective: 2023-06-05

Exact text from the filing

On June 5, 2023, Bone Biologics Corporation (the “Company”) filed an amendment to its Certificate of Incorporation, as amended, (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-30 reverse stock split of its outstanding common stock and warrants.

View on SEC.gov

Browse all governance changes →

Bone Biologics Corp filing history →

Source: SEC EDGAR

accession 0001493152-23-020241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.